Well-known psychedelics like MDMA and psilocybin mushrooms are inching closer to getting regulatory approval for use in treating mental health illnesses. As they do, the Wall Street Journal reports, investors are putting money into lab-made chemicals that start-ups say provide the health benefits without the long, complex psychedelic trips induced by the old-school versions. |